A study indicates that BCL2 dependence, as well as CD38 expression, are significantly linked with the differentiation progression of multiple myeloma (MM).
“CD38 expression on myeloma cells is a critical factor affecting the early response to the anti-CD38 antibody daratumumab,” the researchers wrote. “However, the factors affecting CD38 expression in untreated multiple myeloma are not fully elucidated.”
In this analysis, the researchers observed that CD38 expression was notably lower in MM patients with the translocation t(11;14)-associated immature plasma cell phenotype. Also, they found that CD138, was also reduced in these patients, suggesting that CD38 expression may be associated with the differentiation and maturation stages of myeloma cells, the researchers noted.
Moreover, the investigators observed that BCL2/BCL2L1 was appreciably higher in patients with the immature phenotype expressing B-cell-associated genes. Specifically, BCL2/BCL2L1 ratio and CD38 expression were significantly negatively correlated. “These results suggest that BCL2 dependence, as well as CD38 expression, are deeply associated with the differentiation and maturation stages of myeloma cells. This study highlights the importance of examining t(11;14) and considering cell maturity in myeloma treatment strategies,” the researchers concluded.